Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5923368 | 0.87 | CRHBP (0.50) | GAAMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL13856226 | 0.85 | SMN1; SMN2 (0.50) | MAPTRAB9AKMT2ACYP3A4 | |
| SCHEMBL4099597 | 0.84 | LMNA (0.49) | RAB9APOLBGBA1CYP1A2CYP3A4 | |
| SCHEMBL5923128 | 0.81 | RAB9A (0.44) | MAPTRAB9AKMT2AMEN1HTT | |
| SCHEMBL5922959 | 0.81 | RAB9A (0.55) | GAAMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL5923283 | 0.81 | MAPT (0.58) | GAAMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL12588538 | 0.81 | MAPK1 (0.55) | GAAMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL12588560 | 0.81 | RAB9A (0.60) | RAB9AKMT2AMEN1TP53 | |
| SCHEMBL4108640 | 0.80 | RAB9A (0.64) | GAAMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL5923278 | 0.79 | ALDH1A1 (0.49) | GAAMAPTRAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | PIGS, GUCY1A1, GUCY1B1 | GAA 83/4885MAPT 2982/4885RAB9A 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.